The state of Missouri currently has 39 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
Registry for Stage 2 Type 1 Diabetes
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: Children's Mercy Adelle Hall Campus- Site Number : 8400014, Kansas City, Missouri
Conditions: Type 1 Diabetes
TrialNet Pathway to Prevention of T1D
Recruiting
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: The Children's Mercy Hospital, Kansas City, Missouri
Conditions: Diabetes Mellitus, Type 1
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/26/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
ALL
Ages:
Between 12 years and 28 years
Trial Updated:
06/26/2025
Locations: Washington University Diabetes Center at Barnes Jewish Hospital, St. Louis, Missouri
Conditions: Type 1 Diabetes Mellitus
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/25/2025
Locations: Alliance for Multispecialty Research - Kansas City, Kansas City, Missouri
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Clinical Research Professionals, Chesterfield, Missouri +1 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
Growth Hormone Resistance of Beta-cells
Recruiting
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/23/2025
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Gestational Diabetes, Obesity, Healthy
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Recruiting
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2025
Locations: Clinical Research Professionals, Chesterfield, Missouri +1 locations
Conditions: Type 2 Diabetes (T2D)
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2025
Locations: Clinvest Research, Springfield, Missouri
Conditions: Diabetes Mellitus, Type 2
Bionic Pancreas in CFRD
Recruiting
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to us... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
06/13/2025
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Cystic Fibrosis-related Diabetes
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
06/12/2025
Locations: Saint Louis University, Saint Louis, Missouri
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
06/09/2025
Locations: The Children's Mercy Hospital, Kansas, Missouri
Conditions: Diabetes Mellitus, Type 1